|
**Overview**: Rh Antibody Titer Panel**Introduction**: The Rh Antibody Titer Panel is a diagnostic tool designed to assess Rh alloimmunization using serum samples. In India, Rh incompatibility affects ~5-10 percent of pregnancies in Rh-negative mothers with Rh-positive fetuses, leading to hemolytic disease of the fetus and newborn (HDFN) in ~1-2 per 1000 births if unscreened/untreated. High morbidity from under-testing in rural/low-SES antenatal care (home deliveries, limited labs), delayed anti-D prophylaxis or monitoring leading to severe fetal anemia, hydrops fetalis, or stillbirth. Per obstetrics practices aligned with ICMR, FOGSI, and Indian Society of Perinatology guidelines, the test employs immunoassay for Rh antibody titer and antibody identification over 1-2 days with high accuracy, valuable for monitoring sensitized pregnancies (titer ≥1:16 indicates risk). This diagnostic falls under prenatal screening and targets Rh-negative pregnant women (especially multiparous or history of affected child), addressing accurate detection to guide anti-D, fetal surveillance, or intrauterine transfusion. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise alloimmunization assessment and reducing HDFN burden. Its serum-based approach ensures reliable titer quantification.**Other Names**: Rh Ab Titre Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Rh titer monitoring standard since 1960s; in India, key in antenatal programs.**Purpose**: The test assesses 2 parameters including Rh Antibody Titre to guide Rh alloimmunization assessment, monitor sensitization, inform fetal care.**Test Parameters**: 1. Rh Antibody Titre, 2. Antibody Identification.**Pretest Condition**: No fasting required; patients should be Rh-negative pregnant.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on Rh status, prior pregnancies.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected alloimmunization including fetal death, benefits of monitoring, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and report titer/identification within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Rising titer or anti-D identification indicates risk, necessitating specialist input.**Specialist Consultation**: Fetal medicine specialists should be consulted for management.**Additional Supporting Tests**: Fetal Doppler, MCA-PSV for confirmation.**Test Limitations**: Titer interpretation requires serial monitoring; comprehensive approach required.**References**: Indian Journal of Obstetrics and Gynaecology 2024, Prenatal Studies India 2023. |
